The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis-Reference-Cited by-同舟云学术

The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis

Published:2015-10-20 Issue:3 Volume:63 Page:930-950
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Carbone Marco¹²,Sharp Stephen J.³,Flack Steve¹,Paximadas Dimitrios¹,Spiess Kelly¹,Adgey Carolyn⁴,Griffiths Laura⁵,Lim Reyna⁶,Trembling Paul⁷,Williamson Kate⁸,Wareham Nick J.³,Aldersley Mark⁹,Bathgate Andrew¹⁰,Burroughs Andrew K.¹¹,Heneghan Michael A.¹²,Neuberger James M.⁶,Thorburn Douglas¹¹,Hirschfield Gideon M.¹³,Cordell Heather J.¹⁴,Alexander Graeme J.²,Jones David E.J.⁵,Sandford Richard N.¹,Mells George F.¹²,

Affiliation:

1. Academic Department of Medical Genetics, University of Cambridge; Cambridge United Kingdom

2. Division of Gastroenterology and Hepatology; Addenbrooke's Hospital; Cambridge United Kingdom

3. MRC Epidemiology Unit, University of Cambridge; Cambridge United Kingdom

4. Liver Unit, Royal Victoria Hospital; Belfast United Kingdom

5. Institute of Cellular Medicine, Newcastle University; Newcastle upon Tyne United Kingdom

6. Liver Unit, Queen Elizabeth Hospital; Birmingham United Kingdom

7. Liver Unit, Barts and the London NHS Trust; London United Kingdom

8. Translational Gastroenterology Unit, John Radcliffe Hospital; Oxford United Kingdom

9. Liver Unit, St James's University Hospital; Leeds United Kingdom

10. Scottish Liver Transplant Unit, Royal Infirmary of Edinburgh; Edinburgh United Kingdom

11. Sheila Sherlock Liver Center, The Royal Free London NHS Foundation Trust; London United Kingdom

12. Institute of Liver Studies, King's College Hospital NHS Foundation Trust; London United Kingdom

13. Center for Liver Research and NIHR Biomedical Research Unit, University of Birmingham; Birmingham United Kingdom

14. Institute of Genetic Medicine, Newcastle University; Newcastle upon Tyne United Kingdom

Funder

Isaac Newton Trust, University of Cambridge

Addenbrooke's Charitable Trust (ACT), Cambridge University Hospitals NHS Foundation Trust

PBC Foundation; Intercept Pharmaceuticals, the Wellcome Trust

Medical Research Council (MRC)

MC is a Sheila Sherlock Fellow of the European Association for the Study of the Liver (EASL)

Sackler Trust at the University of Cambridge

National Institute for Health Research Rare Diseases (NIHT-RD) initiative

MRC stratified medicine award

NIHR Comprehensive Research Network (CRN)

Publisher

Wiley

Subject

Hepatology

Reference21 articles.

1. EASL Clinical Practice Guidelines: management of cholestatic liver diseases;European Association for the Study of the Liver;J Hepatol,2009

2. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid;Carbone;Gastroenterology,2013

3. Personalized medicine: risk prediction, targeted therapies and mobile health technology;Hayes;BMC Med,2014

4. Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group;Poupon;N Engl J Med,1994

5. Primary biliary cirrhosis;Lindor;Hepatology,2009

Cited by 281 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sub-optimal therapy of patients with primary biliary cholangitis (PBC) in the real-life stetting of the German PBC cohort;Zeitschrift für Gastroenterologie;2024-09-03

2. Position paper of the Italian Association for the Study of the Liver (AISF): Management and treatment of primary biliary cholangitis;Digestive and Liver Disease;2024-09

3. The External Validation of GLOBE and UK-PBC Risk Scores for Predicting Ursodeoxycholic Acid Treatment Response in a Large U.S. Cohort of Primary Biliary Cholangitis Patients;Journal of Clinical Medicine;2024-08-01

4. Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis;JHEP Reports;2024-07

5. The overlap with metabolic dysfunction‐associated steatotic liver disease negatively affects outcomes of primary biliary cholangitis;Alimentary Pharmacology & Therapeutics;2024-06-25